New TB diagnostic tests for use at the point-of-care level are critical to reach the goals of the End TB Strategy. In spite of extensive research efforts and numerous biomarker candidates, a rapid, simple and accurate non-sputum based test is not yet available. To address this barrier, a web-based platform mapping biomarker research has been developed as a result of a collaborative effort by FIND, McGill and the New Diagnostics Working Group.
The TB biomarker-to-diagnostics database Bm2Dx is an online platform designed to help accelerate biomarker discovery, validation, confirmation and test development. Mapping the status of biomarker research, Bm2Dx provides an overview of the R&D landscape and allows stakeholders to access comprehensive information on biomarker candidates. Its user-friendly interface facilitates advanced search and analysis and enables the dynamic tracking of evidence about biomarker candidates with potential to meet the Target Product Profiles for a non-sputum based test.
Visit website and create account to explore candidates.